imported>AlyInWikiWonderland: /* Tryptamines listed */ Combine tables.

2025-11-20T09:32:05Z

Tryptamines listed: Combine tables.

New page

{{Short description|1997 book by Alexander Shulgin and Ann Shulgin}}
{{Distinguish|Tikal}}
{{Use American English|date=July 2022}}
{{Use mdy dates|date=July 2022}}
{{Infobox book
| name = TiHKAL: The Continuation
| image = Tihkal.jpg
| image_size = 200px
| caption = Cover of ''TiHKAL'', 1st ed.
| author = [[Alexander Shulgin|Alexander]] and [[Ann Shulgin]]
| cover_artist =
| country = United States
| subject = [[Pharmacology]], [[Autobiography]], [[Psychedelic drug]]s
| publisher = [[Transform Press]]
| release_date = 1997
| media_type = Paperback
| pages = ''xxviii'', 804 p.
| isbn = 0-9630096-9-9
| oclc = 38503252
| preceded_by = [[PiHKAL]] (1991)
}}

'''''TiHKAL: The Continuation''''', also known as '''''Tryptamines I Have Known and Loved''''', is a 1997 book written by [[Alexander Shulgin]] and [[Ann Shulgin]].<ref name="Sessa2015">{{cite book | author=Ben Sessa | editor1-last=Ellens | editor1-first=J.H. | editor2-last=D | editor2-first=T.B.R.P. | chapter=Continuing History of Psychedelics in Medical Practices: The Renaissance of Ps chedelic Medical Research | title=The Psychedelic Policy Quagmire: Health, Law, Freedom, and Society | publisher=Bloomsbury Publishing | series=Psychology, Religion, and Spirituality | year=2015 | isbn=979-8-216-13356-8 | url=https://books.google.com/books?id=dKnIEAAAQBAJ&pg=PT50 | access-date=30 January 2025 | page=50}}</ref><ref name="TiHKAL1997">{{cite book | author1 = [[Alexander T. Shulgin]] | author2 = [[Ann Shulgin]] | title = TiHKAL: The Continuation | publisher = [[Transform Press]] | date = 1997 | edition = 1st | location = Berkeley, CA | isbn = 978-0-9630096-9-2 | oclc = 38503252 | url = https://books.google.com/books?id=jl_ik66IumUC | access-date = 30 January 2025 }}</ref> It is about a family of [[psychoactive drug]]s known as [[substituted tryptamine|tryptamine]]s, which includes [[psychedelic drug|psychedelic]]s, other [[hallucinogen]]s, and [[entactogen]]s.<ref name="Sessa2015" /><ref name="TiHKAL1997" /> The book has two halves, and the second part of the book contains detailed entries on 55{{nbsp}}tryptamines.<ref name="TiHKAL1997" /> ''TiHKAL'' is a sequel to ''[[PiHKAL|PiHKAL: A Chemical Love Story]]'' (''Phenethylamines I Have Known and Loved'') (1991).<ref name="Sessa2015" /><ref name="TiHKAL1997" />

==Content==
''TiHKAL'', much like its predecessor ''[[PiHKAL]]'', is divided into two parts.<ref name="TiHKAL1997" /> The first part, for which all rights are reserved, begins with a fictionalized autobiography, picking up where the similar section of ''PiHKAL'' left off; it then continues with a collection of essays on topics ranging from [[psychotherapy]] and the [[Carl Jung|Jungian]] mind to the prevalence of [[dimethyltryptamine|DMT]] in nature, [[ayahuasca]] and the [[war on drugs]].<ref name="TiHKAL1997" />

The second part of ''TiHKAL'', which may be conditionally distributed for non-commercial reproduction {{See below|{{section link||External links}}, below}}, is a detailed [[chemical synthesis|synthesis]] manual for 55{{nbsp}}tryptamines (many discovered by Alexander Shulgin himself), including their [[chemical structure]]s, [[dose (biochemistry)|dose]]s, [[duration of action|duration]]s, and commentary.<ref name="TiHKAL1997" /> It includes entries on compounds including simple tryptamines like [[dimethyltryptamine]] (DMT), [[psilocin]], and [[5-MeO-DMT]], [[substituted α-alkyltryptamine|α-alkyltryptamine]]s like [[α-methyltryptamine]] (AMT), [[substituted β-carboline|β-carboline]]s or [[harmala alkaloid]]s like [[harmaline]], the [[iboga alkaloid]] [[ibogaine]], and [[substituted lysergamide|lysergamide]]s like [[LSD]].<ref name="TiHKAL1997" /> Whereas ''PiHKAL'' had 179{{nbsp}}entries on [[substituted phenethylamine|phenethylamine]]s, ''TiHKAL'' has only 55{{nbsp}}entries.<ref name="PiHKAL">{{CitePiHKAL}}</ref><ref name="TiHKAL1997" /> Shulgin has made the second part freely available on [[Erowid]] while the first part is available only in the printed text.

Members of Shulgin's research who contributed to the experience reports included Shulgin himself, [[Ann Shulgin]], [[Myron Stolaroff]], and Jean Stolaroff, among others.<ref name="BLTC2021">{{cite AV media | people=Connie Littlefield (director, writer), Siobhan Flanagan, [[Alexander Shulgin]] (subject), [[Ann Shulgin]] (subject), Paul F. Daley (subject), [[Myron Stolaroff]] (subject), Jean Stolaroff (subject), Wendy Perry Tucker (subject), Tania Manning (subject), Greg Manning (subject), [[Keeper Trout]] (subject), [[Erowid|Earth and Fire Erowid]], others | date=2021 | title=Better Living Through Chemistry | url=https://betterlivingthroughchemistry.org/ | archive-url=https://tubitv.com/movies/100015889/better-living-through-chemistry | archive-date=21 September 2021 | type=Motion picture | language=English | location= | publisher=Better Living Through Film, Incorporated}}</ref><ref name="PassieBrandt2018">{{cite journal | vauthors = Passie T, Brandt SD | title = Self-Experiments with Psychoactive Substances: A Historical Perspective | journal = Handb Exp Pharmacol | volume = 252 | issue = | pages = 69–110 | date = 2018 | pmid = 30478735 | doi = 10.1007/164_2018_177 | url = | quote = More ambitious explorations of subjective effects elicited by a series of new psychoactive substances developed by Shulgin were conducted by his close associate and psychologist, Myron Stolaroff. Following SEs with LSD in the mid-1950s, Stolaroff became involved in scientific research on psychedelics. After the control of most psychedelic drugs in the 1970s, Stolaroff conducted SEs with newly synthesized psychedelics 2C-B, 2C-E, 2C-T-2, 2C-T-7, 2C-T4, 2C-T-21, and MEM but also MDMA. Besides Shulgin, Stolaroff was the first who systematically explored the psychological states and their possible uses but under noncontrolled conditions (Stolaroff 1994). He understood his research as an attempt “to make the unconscious conscious” and to give some “guidelines for the proper and safe use of psychedelic drugs in therapy and for spiritual growth” (Stolaroff 1994, pp. 13–14).}}</ref>

==Response==
As with ''[[PiHKAL]]'', the Shulgins were motivated to release the synthesis information as a way to protect the public's access to information about psychedelic compounds, a goal Alexander Shulgin has noted many times.<ref name="nyt"> {{cite news |first = Drake |last = Bennett |url = https://www.nytimes.com/2005/01/30/magazine/30ECSTASY.html |title = Dr. Ecstasy |work = New York Times Magazine |date = 2005-01-30 |access-date = 2006-07-08 }}</ref> Following a raid of his laboratory in 1994 by the [[Drug Enforcement Administration|United States DEA]],<ref> {{cite web | title = DEA Raid of Shulgin's Laboratory | publisher = Erowid | date = 2004-01-08 | url = http://www.erowid.org/culture/characters/shulgin_alexander/shulgin_alexander_raid.shtml | access-date = 2006-07-08 }}</ref> Richard Meyer, spokesman for DEA's San Francisco Field Division, stated that "It is our opinion that those books [referring to the previous work, ''PiHKAL'' are pretty much cookbooks on how to make illegal drugs. Agents tell me that in clandestine labs that they have raided, they have found copies of those books."

==Notable compounds==
Some compounds in ''TiHKAL'', including [[dimethyltryptamine]] (DMT), [[psilocybin]] (4-PO-DMT), [[psilocin]] (4-HO-DMT), [[bufotenin]] (5-HO-DMT), [[5-MeO-DMT]], [[α-methyltryptamine]] (AMT), [[lysergic acid diethylamide]] (LSD), [[harmaline]], and [[ibogaine]], are widely known and/or used [[hallucinogen]]s.<ref name="TiHKAL1997" />

==Tryptamines listed==
{{Sticky}}
{| class="wikitable sticky-header sortable" style="font-size:small;"
! #
! Substance
! Chemical name
! Group
! Dosea
! Duration
! Link
|-
| 1
| [[AL-LAD]] (6-allyl-6-nor-LSD)
| 6-Allyl-''N'',''N''-diethyl-NL
| [[Substituted lysergamide|Lysergamide]]
| 80–160 μg
| 6–8 hours
| [https://www.erowid.org/library/books_online/tihkal/tihkal01.shtml]
|-
| 2
| [[Dibutyltryptamine|DBT]] (dibutyltryptamine)
| ''N'',''N''-Dibutyl-T
| [[Substituted tryptamine|Tryptamine]]
| Unknown
| Unknown
| [https://www.erowid.org/library/books_online/tihkal/tihkal02.shtml]
|-
| 3
| [[Diethyltryptamine|DET]] (diethyltryptamine)
| ''N'',''N''-Diethyl-T
| Tryptamine
| 50–100 mg
| 2–4 hours
| [https://www.erowid.org/library/books_online/tihkal/tihkal03.shtml]
|-
| 4
| [[Diisopropyltryptamine|DiPT]] (diisopropyltryptamine)
| ''N'',''N''-Diisopropyl-T
| Tryptamine
| 25–100 mg
| 6–8 hours
| [https://www.erowid.org/library/books_online/tihkal/tihkal04.shtml]
|-
| 5
| [[5-MeO-AMT|α,''O''-DMS]] (5-MeO-AMT)
| 5-Methoxy-α-methyl-T
| [[Substituted α-alkyltryptamine|α-Alkyltryptamine]]
| 2.5–4.5 mg
| 12–18 hours
| [https://www.erowid.org/library/books_online/tihkal/tihkal05.shtml]
|-
| 6
| [[Dimethyltryptamine|DMT]] (dimethyltryptamine)
| ''N'',''N''-Dimethyl-T
| Tryptamine
| Variousb
| Up to 1 hour
| [https://www.erowid.org/library/books_online/tihkal/tihkal06.shtml]
|-
| 7
| [[2,α-DMT]] (2-methyl-AMT)
| 2,α-Dimethyl-T
| α-Alkyltryptamine
| 300–500 mg
| 7–10 hours
| [https://www.erowid.org/library/books_online/tihkal/tihkal07.shtml]
|-
| 8
| [[α,N-DMT|α,''N''-DMT]] (''N''-methyl-AMT)
| α,''N''-Dimethyl-T
| α-Alkyltryptamine
| 50–100 mg
| 6–8 hours
| [https://www.erowid.org/library/books_online/tihkal/tihkal08.shtml]
|-
| 9
| [[Dipropyltryptamine|DPT]] (dipropyltryptamine)
| ''N'',''N''-Dipropyl-T
| Tryptamine
| 100–250 mg
| 2–4 hours
| [https://www.erowid.org/library/books_online/tihkal/tihkal09.shtml]
|-
| 10
| [[Ethylisopropyltryptamine|EiPT]] (ethylisopropyltryptamine)
| ''N''-Ethyl-''N''-isopropyl-T
| Tryptamine
| 24–40 mg
| 4–6 hours
| [https://www.erowid.org/library/books_online/tihkal/tihkal10.shtml]
|-
| 11
| [[α-Ethyltryptamine|α-ET]] (AET; α-ethyltryptamine)
| α-Ethyl-T
| α-Alkyltryptamine
| 100–150 mg
| 6–8 hours
| [https://www.erowid.org/library/books_online/tihkal/tihkal11.shtml]
|-
| 12
| [[ETH-LAD]] (6-ethyl-6-nor-LSD)
| 6,''N'',''N''-Triethyl-NL
| Lysergamide
| 40–150 μg
| 8–12 hours
| [https://www.erowid.org/library/books_online/tihkal/tihkal12.shtml]
|-
| 13
| [[Harmaline]] (dihydroharmine)
| 3,4-Dihydro-7-methoxy-1-methyl-BC
| [[Substituted β-carboline|β-Carboline]]
| 150–300 mg
| 5–8 hours
| [https://www.erowid.org/library/books_online/tihkal/tihkal13.shtml]
|-
| 14
| [[Harmine]]
| 7-Methyoxy-1-methyl-BC
| β-Carboline
| >300 mg
| Unknown
| [https://www.erowid.org/library/books_online/tihkal/tihkal14.shtml]
|-
| 15
| [[4-HO-DBT]]
| ''N'',''N''-Dibutyl-4-hydroxy-T
| [[Substituted 4-hydroxytryptamine|4-Hydroxytryptamine]]
| >20 mg
| Unknown
| [https://www.erowid.org/library/books_online/tihkal/tihkal15.shtml]
|-
| 16
| [[4-HO-DET]]
| ''N'',''N''-Diethyl-4-hydroxy-T
| 4-Hydroxytryptamine
| 10–25 mg
| 4–6 hours
| [https://www.erowid.org/library/books_online/tihkal/tihkal16.shtml]
|-
| 17
| [[4-HO-DiPT]]
| ''N'',''N''-Diisopropyl-4-hydroxy-T
| 4-Hydroxytryptamine
| 15–20 mg
| 2–3 hours
| [https://www.erowid.org/library/books_online/tihkal/tihkal17.shtml]
|-
| 18
| [[Psilocin|4-HO-DMT]] (psilocin)
| ''N'',''N''-Dimethyl-4-hydroxy-T
| 4-Hydroxytryptamine
| 10–20 mg
| 3–6 hours
| [https://www.erowid.org/library/books_online/tihkal/tihkal18.shtml]
|-
| 19
| [[Bufotenin|5-HO-DMT]] (bufotenin)
| ''N'',''N''-Dimethyl-5-hydroxy-T
| [[Substituted 5-hydroxytryptamine|5-Hydroxytryptamine]]
| 8–16 mg {{Abbr|i.v.|intravenous injection}}
| 1–2 hours
| [https://www.erowid.org/library/books_online/tihkal/tihkal19.shtml]
|-
| 20
| [[4-HO-DPT]]
| ''N'',''N''-Dipropyl-4-hydroxy-T
| 4-Hydroxytryptamine
| Unknown
| Unknown
| [https://www.erowid.org/library/books_online/tihkal/tihkal20.shtml]
|-
| 21
| [[4-HO-MET]]
| ''N''-Ethyl-4-hydroxy-''N''-methyl-T
| 4-Hydroxytryptamine
| 10–20 mg
| 4–6 hours
| [https://www.erowid.org/library/books_online/tihkal/tihkal21.shtml]
|-
| 22
| [[4-HO-MiPT]]
| 4-Hydroxy-''N''-isopropyl-''N''-methyl-T
| 4-Hydroxytryptamine
| 12–25 mg
| 4–6 hours
| [https://www.erowid.org/library/books_online/tihkal/tihkal22.shtml]
|-
| 23
| [[4-HO-MPT]]
| 4-Hydroxy-''N''-methyl-''N''-propyl-T
| 4-Hydroxytryptamine
| Unknown
| Unknown
| [https://www.erowid.org/library/books_online/tihkal/tihkal23.shtml]
|-
| 24
| [[4-HO-pyr-T]]
| 4-Hydroxy-''N'',''N''-tetramethylene-T
| [[Pyrrolidinylethylindole]]
| >20 mg
| Unknown
| [https://www.erowid.org/library/books_online/tihkal/tihkal24.shtml]
|-
| 25
| [[Ibogaine]]
| A complexly substituted-T
| [[Azepinoindole]]
| Variousc
| "Quite long"
| [https://www.erowid.org/library/books_online/tihkal/tihkal25.shtml]
|-
| 26
| [[LSD]] (METH-LAD)
| ''N'',''N''-Diethyl-L
| Lysergamide
| 60–200 μg
| 8–12 hours
| [https://www.erowid.org/library/books_online/tihkal/tihkal26.shtml]
|-
| 27
| [[Methylbutyltryptamine|MBT]] (methylbutyltryptamine)
| ''N''-Butyl-''N''-methyl-T
| Tryptamine
| 250–400 mg
| 4–6 hours
| [https://www.erowid.org/library/books_online/tihkal/tihkal27.shtml]
|-
| 28
| [[4,5-MDO-DiPT]]
| ''N'',''N''-Diisopropyl-4,5-methylenedioxy-T
| Other
| >25 mg
| Unknown
| [https://www.erowid.org/library/books_online/tihkal/tihkal28.shtml]
|-
| 29
| [[5,6-MDO-DiPT]]
| ''N'',''N''-Diisopropyl-5,6-methylenedioxy-T
| Other
| Unknown
| Unknown
| [https://www.erowid.org/library/books_online/tihkal/tihkal29.shtml]
|-
| 30
| [[4,5-MDO-DMT]]
| ''N'',''N''-Dimethyl-4,5-methylenedioxy-T
| Other
| Unknown
| Unknown
| [https://www.erowid.org/library/books_online/tihkal/tihkal30.shtml]
|-
| 31
| [[5,6-MDO-DMT]]
| ''N'',''N''-Dimethyl-5,6-methylenedioxy-T
| Other
| >5 mg
| Unknown
| [https://www.erowid.org/library/books_online/tihkal/tihkal31.shtml]
|-
| 32
| [[5,6-MDO-MiPT]]
| ''N''-Isopropyl-''N''-methyl-5,6-methylenedioxy-T
| Other
| >50 mg
| Unknown
| [https://www.erowid.org/library/books_online/tihkal/tihkal32.shtml]
|-
| 33
| [[2-Me-DET]] (2-methyl-DET)
| ''N'',''N''-Diethyl-2-methyl-T
| Other
| 80–120 mg
| 6–8 hours
| [https://www.erowid.org/library/books_online/tihkal/tihkal33.shtml]
|-
| 34
| [[2,N,N-TMT|2-Me-DMT]] (2-methyl-DMT)
| 2,''N'',''N''-Trimethyl-T
| Other
| 50–100 mg
| 4–6 hours
| [https://www.erowid.org/library/books_online/tihkal/tihkal34.shtml]
|-
| 35
| [[Melatonin (drug)|Melatonin]] (5-MeO-NAcT)
| ''N''-Acetyl-5-methoxy-T
| [[Substituted N-acetyltryptamine|''N''-Acetyltryptamine]]
| 1–10 mg
| "A few hours"
| [https://www.erowid.org/library/books_online/tihkal/tihkal35.shtml]
|-
| 36
| [[5-MeO-DET]]
| ''N'',''N''-Diethyl-5-methoxy-T
| [[Substituted 5-methoxytryptamine|5-Methoxytryptamine]]
| 1–3 mg
| 3–4 hours
| [https://www.erowid.org/library/books_online/tihkal/tihkal36.shtml]
|-
| 37
| [[5-MeO-DiPT]]
| ''N'',''N''-Diisopropyl-5-methoxy-T
| 5-Methoxytryptamine
| 6–12 mg
| 4–8 hours
| [https://www.erowid.org/library/books_online/tihkal/tihkal37.shtml]
|-
| 38
| [[5-MeO-DMT]]
| 5-Methoxy-''N'',''N''-dimethyl-T
| 5-Methoxytryptamine
| Variousd
| 1–2 hours
| [https://www.erowid.org/library/books_online/tihkal/tihkal38.shtml]
|-
| 39
| [[4-MeO-MiPT]]
| ''N''-Isopropyl-4-methoxy-''N''-methyl-T
| Other
| 20–30 mg
| 4–6 hours
| [https://www.erowid.org/library/books_online/tihkal/tihkal39.shtml]
|-
| 40
| [[5-MeO-MiPT]]
| ''N''-Isopropyl-5-methoxy-''N''-methyl-T
| 5-Methoxytryptamine
| 4–6 mge 
| 4–6 hours
| [https://www.erowid.org/library/books_online/tihkal/tihkal40.shtml]
|-
| 41
| [[5,6-MeO-MiPT]]
| 5,6-Dimethoxy-''N''-isopropyl-''N''-methyl-T
| Other
| >75 mg
| Unknown
| [https://www.erowid.org/library/books_online/tihkal/tihkal41.shtml]
|-
| 42
| [[5-MeO-NMT]]
| 5-Methoxy-''N''-methyl-T
| 5-Methoxytryptamine
| Unknown
| Unknown
| [https://www.erowid.org/library/books_online/tihkal/tihkal42.shtml]
|-
| 43
| [[5-MeO-pyr-T]]
| 5-Methoxy-''N'',''N''-tetramethylene-T
| Pyrrolidinylethylindole
| 0.5–2 mg
| "Several hours"
| [https://www.erowid.org/library/books_online/tihkal/tihkal43.shtml]
|-
| 44
| [[6-MeO-THH]]
| 6-Methoxy-1-methyl-1,2,3,4-tetrahydro-BC
| β-Carboline
| Unknown
| Unknown
| [https://www.erowid.org/library/books_online/tihkal/tihkal44.shtml]
|-
| 45
| [[5-MeO-TMT]]
| 5-Methoxy-2,''N'',''N''-trimethyl-T
| Other
| 75–150 mg
| 5–10 hours
| [https://www.erowid.org/library/books_online/tihkal/tihkal45.shtml]
|-
| 46
| [[5-MeS-DMT]]
| ''N'',''N''-Dimethyl-5-methylthio-T
| Other
| 15–30 mg {{Abbr|sm.|smoked}}
| <1 hour
| [https://www.erowid.org/library/books_online/tihkal/tihkal46.shtml]
|-
| 47
| [[Methylisopropyltryptamine|MiPT]] (methylisopropyltryptamine)
| ''N''-Isopropyl-''N''-methyl-T
| Tryptamine
| 10–25 mg
| 3–4 hours
| [https://www.erowid.org/library/books_online/tihkal/tihkal47.shtml]
|-
| 48
| [[α-Methyltryptamine|α-MT]] (AMT; α-methyltryptamine)
| α-Methyl-T
| α-Alkyltryptamine
| 15–30 mgf 
| 12–16 hours
| [https://www.erowid.org/library/books_online/tihkal/tihkal48.shtml]
|-
| 49
| [[N-Ethyltryptamine|NET]] (''N''-ethyltryptamine)
| ''N''-Ethyl-T
| Tryptamine
| Unknown
| Unknown
| [https://www.erowid.org/library/books_online/tihkal/tihkal49.shtml]
|-
| 50
| [[N-Methyltryptamine|NMT]] (''N''-methyltryptamine)
| ''N''-Methyl-T
| Tryptamine
| Unknown
| Unknown
| [https://www.erowid.org/library/books_online/tihkal/tihkal50.shtml]
|-
| 51
| [[PRO-LAD]] (6-propyl-6-nor-LSD)
| 6-Propyl-NL
| Lysergamide
| 100–200 μg
| 6–8 hours
| [https://www.erowid.org/library/books_online/tihkal/tihkal51.shtml]
|-
| 52
| [[pyr-T]] (pyrrolidinyltryptamine)
| ''N'',''N''-Tetramethylene-T
| Pyrrolidinylethylindole
| Unknown
| Unknown
| [https://www.erowid.org/library/books_online/tihkal/tihkal52.shtml]
|-
| 53
| [[Tryptamine|T]] (tryptamine)
| Tryptamine
| Tryptamine
| 250 mg {{Abbr|i.v.|intravenous injection}}
| "Very short"
| [https://www.erowid.org/library/books_online/tihkal/tihkal53.shtml]
|-
| 54
| [[Tetrahydroharmine]] (THH)
| 7-Methoxy-1-methyl-1,2,3,4-tetrahydro-BC
| β-Carboline
| 300 mg
| Unknown
| [https://www.erowid.org/library/books_online/tihkal/tihkal54.shtml]
|-
| 55
| [[α,N,O-TMS|α,''N'',''O''-TMS]] (5-MeO-α,''N''-DMT)
| α,''N''-Dimethyl-5-methoxy-T
| α-Alkyltryptamine
| 10–20 mg
| 6–8 hours
| [https://www.erowid.org/library/books_online/tihkal/tihkal55.shtml]
|-
| 56
| [[5-MeO-DALT]]g
| 5-Methoxy-''N'',''N''-diallyl-T
| 5-Methoxytryptamine
| 12–20 mg
| 2–4 hours
| [https://www.erowid.org/chemicals/5meo_dalt/5meo_dalt_info1.shtml] [https://isomerdesign.com/pihkal/read/tk/56]
|-
| 57
| [[Diallyltryptamine|DALT]] (diallyltryptamine)g
| ''N'',''N''-Diallyl-T
| Tryptamine
| >40 mg
| Unknown
| [https://isomerdesign.com/pihkal/read/tk/57]
|- class="sortbottom"
| colspan="7" style="width: 1px; background-color:var(--background-color-notice-subtle,#eaecf0); color:inherit; text-align: center;" | '''Footnotes:''' a = [[Dose (biochemistry)|Dose]] and [[duration of action|duration]] are [[oral administration|orally]] unless otherwise specified. b = [[Dimethyltryptamine|DMT]] doses are >350{{nbsp}}mg orally, 60–100{{nbsp}}mg [[intramuscular injection|intramuscularly]], [[subcutaneous injection|subcutaneously]], or [[smoking|smoked]], and 4–30{{nbsp}}mg [[intravenous injection|intravenously]]. c = [[Ibogaine]] dose is "from hundreds of [mg] up to [1{{nbsp}}g] or more". d = [[5-MeO-DMT]] doses are 6–20{{nbsp}}mg smoked and 2–3 mg intravenously. e = [[5-MeO-MiPT]] doses are 4–6{{nbsp}}mg orally and 12–20{{nbsp}}mg smoked. f = [[α-Methyltryptamine|AMT]] doses are 15–30 mg orally and 5–20 mg smoked. g = The [[5-MeO-DALT]] (#56) and [[DALT (drug)|DALT]] (#57) entries were not included in the published version of ''TiHKAL'' and were subsequently released in 2004.<ref name="MorrisSmith2010">{{cite web | vauthors = Morris H, Smith A | title=The Last Interview With Alexander Shulgin | website=VICE | date=2010-05-02 | url=https://www.vice.com/en/article/the-last-interview-with-alexander-shulgin-423-v17n5/}}</ref>
|}

==See also==
* [[Bibliography of Alexander Shulgin]]
* ''[[PiHKAL]]'' (''Phenethylamines I Have Known and Loved'') (1991)
* ''[[The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds]]'' (2011)
* [[List of psychedelic literature]]
* [[Substituted tryptamine]]
* [[Substituted β-carboline]] and [[harmala alkaloid]]
* [[Azepinoindole]] and [[iboga alkaloid]]
* [[Substituted lysergamide]]

==References==
{{Reflist}}

==External links==

* [http://www.erowid.org/library/books_online/tihkal/tihkal.shtml Erowid Online Books: ''TiHKAL: The Continuation'' by Alexander & Ann Shulgin]
* [http://www.shulgin.es "Shulgin in Spanish" Project – Information on the first complete translation of ''PiHKAL'' and ''TiHKAL'' into Spanish]
* [http://isomerdesign.com/PiHKAL/?domain=tk ''TiHKAL'' • Info: A Visual Index and Map of ''TiHKAL: The Continuation'' by Alexander & Ann Shulgin]
* [https://www.transformpress.com Transform Press – Publisher of ''TiHKAL'']

{{Tryptamines}}
{{Psychedelics}}
{{Chemical classes of psychoactive drugs}}

{{DEFAULTSORT:Tihkal}}

[[Category:1997 non-fiction books]]
[[Category:Alexander Shulgin]]
[[Category:Psychedelic drug research]]
[[Category:Psychedelic literature]]
[[Category:Psychedelic tryptamines|*]]
[[Category:Science books]]

TiHKAL - Revision history

imported>AlyInWikiWonderland: /* Tryptamines listed */ Combine tables.